Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Takeda pays $60mm up front for rights to AMAG's Feraheme; rights returned

Executive Summary

Takeda Pharmaceutical Co. Ltd. has licensed exclusive rights to sell AMAG Pharmaceuticals Inc.'s (anemia, cardiovascular, and oncology) intravenous Feraheme (ferumoxytol) for all indications in Europe, Canada, India, Turkey, the Commonwealth of Independent States, and Asia Pacific countries excluding China (where 3SBio already has rights), Japan, and Taiwan.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies